YAMASA CORPORATION Patent applications |
Patent application number | Title | Published |
20140356481 | BREWED SOY SAUCE AND METHOD OF PRODUCING THE BREWED SOY SAUCE - The present invention provides a brewed soy sauce that has light color and reduced smell with a robust taste. In the brewed soy sauce, HEMF is less than 15 ppm. Glutamic acid is 0.9% (w/v) or more. Lactic acid and acetic acid are respectively 0.1% (w/v) or more. Reducing sugar is 1.5% (w/v) or less. Levulinic acid is less than 0.01% (w/v). And, pH is 4.5-5.5. The brewed soy sauce is produced as follows: First, a raw material is prepared from a plant protein-source material and a low-starch carbohydrate-source material. Then, koji is made by inoculating koji mold to the prepared raw material. Next, salt water is added to the koji, and the mixture of the salt water and koji is fermented. At least 5 days after initiating the fermentation, yeast belonging to | 12-04-2014 |
20140206042 | METHOD OF ENZYMATICALLY SYNTHESIZING 3' -PHOSPHOADENOSINE-5'-PHOSPHOSULFATE - The invention provides a method for producing 3′-phosphoadenosine 5′-phosphosulfate (PAPS), the method including subjecting ATP to sulfation and phosphorylation by use of adenosine 5′-triphosphate sulfurylase (ATPS) and adenosine 5′-phosphosulfate kinase (APSK), wherein an adenosine 5′-triphosphate (ATP) supply/regeneration system including adenosine 5′-monophosphate (AMP), polyphosphate, polyphosphate-driven nucleoside 5′-diphosphate kinase (PNDK), and polyphosphate:AMP phosphotransferase (PAP), or an adenosine 5′-triphosphate (ATP) supply/regeneration system including adenosine 5′-monophosphate (AMP), polyphosphate, polyphosphate-driven nucleoside 5′-diphosphate kinase (PNDK), and adenylate kinase (ADK) is employed instead of ATP. | 07-24-2014 |
20130245046 | NOVEL 2-ALKYNYL-N9-PROPARGYLADENINE AND MEDICINAL USE THEREOF - In the present invention, a novel 2-alkynyl-N9-propargyladenine represented by formula (I) | 09-19-2013 |
20120225837 | MEDICINAL AGENT FOR DISEASE ASSOCIATED WITH EPSTEIN-BARR VIRUS, AND METHOD FOR SCREENING OF THE MEDICINAL AGENT - 1-(2-Fluoro-4-thio-β-D-arabinofuranosyl)-5-methyluracil exhibits an anti-EB virus activity, and is therefore effective as a prophylactic or therapeutic agent for a disease associated with an EB virus. Each of a plasmid capable of expressing EB virus-TK and a plasmid capable of expressing human-TK is introduced into a TK-defect cell, thereby producing two types of cells respectively having the plasmids introduced therein. By using the two types of cells, it is possible to screen a medicinal agent which has cytotoxicity against the cell having the plasmid capable of expressing EB virus-TK introduced therein but has no toxicity against the cell having the plasmid capable of expressing human-TK introduced therein. In this manner, it becomes possible to screen a medicinal agent which specifically exhibits an anti-EB virus activity. | 09-06-2012 |
20110189709 | METHOD FOR DETECTING HEPATIC INJURY DUE TO ANTITHYROID DRUG - The present invention relates a detecting method of distinguishing a temporary liver function test abnormalities by a thyrotoxicosis from a drug-induced hepatic injury by an antithyroid drug using a blood test and the likes, which is performed in a simple manner and with specificity. In the course of treating Graves' disease using an antithyroid drug, it is possible to differentiate a temporary liver function test abnormalities resulted from a thyrotoxicosis from a drug-induced hepatic injury resulted from the antithyroid drug, and therefore to detect the drug-induced hepatic injury with specificity by assaying a level of OCT in a body sample from a patient. In other words, it is possible to diagnose as a drug-induced hepatic injury if a blood OCT level in the sample from the patient is elevated compared to a level prior to administering the antithyroid drug or a blood OCT level from normal persons. Meanwhile, if the OCT level is not changed in spite of elevated levels of transaminases in the sample, it is possible to continue the treatment without discontinuing the drug administration since liver function test abnormalities in this case can be judged as temporary abnormalities owing to metabolic alteration, not as a drug-induced hepatic injury. | 08-04-2011 |
20100330563 | MEDICINAL AGENT FOR DISEASE ASSOCIATED WITH EPSTEIN-BARR VIRUS, AND METHOD FOR SCREENING OF THE MEDICINAL AGENT - 1-(2-Fluoro-4-thio-β-D-arabinofuranosyl)-5-methyluracil exhibits an anti-EB virus activity, and is therefore effective as a prophylactic or therapeutic agent for a disease associated with an EB virus. Each of a plasmid capable of expressing EB virus-TK and a plasmid capable of expressing human-TK is introduced into a TK-defect cell, thereby producing two types of cells respectively having the plasmids introduced therein. By using the two types of cells, it is possible to screen a medicinal agent which has cytotoxicity against the cell having the plasmid capable of expressing EB virus-TK introduced therein but has no toxicity against the cell having the plasmid capable of expressing human-TK introduced therein. In this manner, it becomes possible to screen a medicinal agent which specifically exhibits an anti-EB virus activity. | 12-30-2010 |
20100216985 | STABLE CYSTAL OF PROTECTED PSEUDOURIDINE - A stable and high-purity protected pseudouridine in crystal form is provided represented by the following structural formula: | 08-26-2010 |
20100209953 | METHOD OF DETERMINING CARBONIC ANHYDRASE I ACTIVITY - A method for determining hydrolase activity of carbonic anhydrase I (CAI) in a sample which employs, combination of a substrate and an inhibitor. The substrate is a substrate having higher reactivity with CAI than with CAII selected from 2-hydroxy-5-nitro-α-toluenesulfonic acid sultone, a o-nitrophenyl ester, a p-nitropheylthio ester, and a β-naphthyl ester or a substrate having reactivity with both CAI and CAII selected from the group consisting of a p-nitrophenyl ester and a α-naphthyl ester. The substrate having higher reactivity with CAI than with CAII is a substrate that reacts with CAI in an amount, per amount of enzyme protein, twice or more the amount of substrate reacting with CAII, under identical substrate concentrations and reaction times and that specifically binds to CAI and serves as a substrate for hydrolase activity. The inhibitor is an inhibitor inhibiting a hydrolase other than CA, a CA inhibitor inhibiting both CAI and CAII, or a CA inhibitor inhibiting CAI more potently than CAII. | 08-19-2010 |
20100168366 | NOVEL SYNTHETIC N-LINKED SIALO-GLYCAN-CONTAINING POLYMER AND METHOD FOR PRODUCING THE SAME - A polymer containing an N-linked sialo-glycan wherein a sialo-glycan is condensed to a γ-polyglutamic acid using a chemical compound having an amino group on one end and a carboxyl group on another end and represented by the structural formula (I). Formula (I) (In the formula, Z means a hydroxy group or a residue represented by the formula (II), and n represents an integer of 10 or more, with the proviso that any one or more of the Z's is represented by the formula in (II).) Formula (II) (In the formula, X means a hydroxy group or an acetylamino group, Y | 07-01-2010 |
20100016567 | PROCESS FOR PRODUCING DI(PYRIMIDINE NUCLEOSIDE 5'-)POLYPHOSPHATE - A di(pyrimidine nucleoside 5′-)polyphosphate is synthesized by converting a pyrimidine nucleoside 5′-triphosphate into a pyrimidine nucleoside 5′-cyclic triphosphate by use of a condensing agent, and subsequently reacting the pyrimidine nucleoside 5′-cyclic triphosphate with a pyrimidine nucleotide in the presence of a salt of a metal selected from among magnesium, manganese, and iron. | 01-21-2010 |
20090239309 | METHOD OF STABILIZING PULMONARY SURFACTANT PROTEIN - The present invention relates to a method for long-term stabilizing a pulmonary surfactant protein, to a stabilized aqueous solution containing a pulmonary surfactant protein, and to a kit for assaying a pulmonary surfactant protein which kit contains, as a component reagent, a stabilized aqueous solution containing a pulmonary surfactant protein. | 09-24-2009 |
20090215114 | METHOD OF ENZYMATICALLY SYNTHESIZING 3' -PHOSPHOADENOSINE-5' -PHOSPHOSULFATE - The invention provides a method for producing 3′-phosphoadenosine 5′-phosphosulfate (PAPS), the method including subjecting ATP to sulfation and phosphorylation by use of adenosine 5′-triphosphate sulfurylase (ATPS) and adenosine 5′-phosphosulfate kinase (APSK), wherein an adenosine 5′-triphosphate (ATP) supply/regeneration system including adenosine 5′-monophosphate (AMP), polyphosphate, polyphosphate-driven nucleoside 5′-diphosphate kinase (PNDK), and polyphosphate:AMP phosphotransferase (PAP), or an adenosine 5′-triphosphate (ATP) supply/regeneration system including adenosine 5′-monophosphate (AMP), polyphosphate, polyphosphate-driven nucleoside 5′-diphosphate kinase (PNDK), and adenylate kinase (ADK) is employed instead of ATP. | 08-27-2009 |
20090118491 | STABLE SALT OF 3'-PHOSPHOADENOSINE 5'-PHOSPHOSULFATE - The present invention provides a stable salt of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) and a production method therefor. | 05-07-2009 |
20090118224 | AGENT AGAINST PSYCHOSOCIAL STRESSES - To provide a novel anti-psychosocial stress agent which is highly safety and can be continuously taken, more particularly, a novel anti-psychosocial stress agent which prevents or alleviates psychosocial stress. | 05-07-2009 |
20090111136 | METHOD FOR DETECTION, DETERMINATION OR PREDICTION OF HEPATIC DISORDER - The invention relates to a method for examining a hepatic disorder (e.g., NASH), which is less invasive and highly sensitive and which can be performed in a simple manner. According to the method, the level of a mitochondrion-derived protein (e.g., ornithine carbamoyltransferase or glutamate dehydrogenase) of a blood sample from a patient suffering metabolic syndrome and/or non-alcoholic fatty liver disease is measured, and the measured protein level is compared with an averaged value of protein levels of healthy volunteers, whereby whether or not the patient has a hepatic disorder (e.g., NASH) is determined. | 04-30-2009 |
20090092593 | THERAPEUTIC DRUG FOR HEART DISEASE AND VIRUS DISEASE - The present invention is related to provide a therapeutic drug for heart diseases and viral diseases. The invention provides a therapeutic drug for heart diseases and viral diseases, comprising a free immunoglobulin light chain or a constitutive polypeptide thereof as an active ingredient. | 04-09-2009 |
20090018327 | SUGAR CHAIN CONTAINING 4-POSITION HALOGENATED GALACTOSE AND APPLICATION THEREOF - The present invention is directed to, for example, an oligosaccharide having at an end thereof a 4-position halogenated galactose residue represented by formula (I): | 01-15-2009 |